Andreas Gerber-Grote
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Gerber-Grote has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Frank Gerd Sandmann
Robert Koch Institute
3 shared publications - Massimo Pettoello-Mantovani
European Pediatric Association, Union of National European Pediatric societies and Associations, Berlin, Germany; Italian Academy of Pediatrics, Milan, Italy; Department of Pediatrics, Institute for Scientific Research «Casa Sollievo», University of Foggia, Foggia, Italy
3 shared publications - Stefan K. Lhachimi
Institute for Public Health and Nursing Research, University of Bremen, Bremen, Germany
3 shared publications - Andrea Icks
German Center for Diabetes Research, Neuherberg, Germany
2 shared publications Anja Schwalm
2 shared publications- Charalabos-Markos Dintsios
Institute for Health Services Research and Health Economics, Centre for Health and Society, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 12 August 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (16) , 6569
Unconscious Bias among Health Professionals: A Scoping Review
Background: Unconscious biases are one of the causes of health disparities. Health professionals have prejudices against patients due to their race, gender, or other factors without their conscious knowledge. This review aimed to provide an overview of research on unconscious bias among health professionals and to investigate the biases that exist in different regions of the world, the health professions that are considered, and the research gaps that still exist. Methods: We conducted a scoping review by systematically searching PubMed/MEDLINE, CINAHL, PsycINFO, PsycARTICLES, and AMED. All records were double-screened and included if they were published between 2011 and 2021. Results: A total of 5186 records were found. After removing duplicates (n = 300), screening titles and abstracts (n = 4210), and full-text screening (n = 695), 87 articles from 81 studies remained. Studies originated from North America (n = 60), Europe (n = 13), and the rest of the world (n = 6), and two studies were of global scope. Racial bias was investigated most frequently (n = 46), followed by gender bias (n = 11), weight bias (n = 10), socio-economic status bias (n = 9), and mental illness bias (n = 7). Most of the studies were conducted by physicians (n = 51) and nurses (n = 20). Other health care professionals were rarely included in these studies. Conclusions: Most studies show that health professionals have an implicit bias. Racial biases among physicians and nurses in the USA are well confirmed. Research is missing on other biases from other regions and other health professions.
- 12 August 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (16) , 6569
Top Cited PapersOpen AccessUnconscious Bias among Health Professionals: A Scoping Review
Background: Unconscious biases are one of the causes of health disparities. Health professionals have prejudices against patients due to their race, gender, or other factors without their conscious knowledge. This review aimed to provide an overview of research on unconscious bias among health professionals and to investigate the biases that exist in different regions of the world, the health professions that are considered, and the research gaps that still exist. Methods: We conducted a scoping review by systematically searching PubMed/MEDLINE, CINAHL, PsycINFO, PsycARTICLES, and AMED. All records were double-screened and included if they were published between 2011 and 2021. Results: A total of 5186 records were found. After removing duplicates (n = 300), screening titles and abstracts (n = 4210), and full-text screening (n = 695), 87 articles from 81 studies remained. Studies originated from North America (n = 60), Europe (n = 13), and the rest of the world (n = 6), and two studies were of global scope. Racial bias was investigated most frequently (n = 46), followed by gender bias (n = 11), weight bias (n = 10), socio-economic status bias (n = 9), and mental illness bias (n = 7). Most of the studies were conducted by physicians (n = 51) and nurses (n = 20). Other health care professionals were rarely included in these studies. Conclusions: Most studies show that health professionals have an implicit bias. Racial biases among physicians and nurses in the USA are well confirmed. Research is missing on other biases from other regions and other health professions.
- Open Access
- 31 July 2018
- Published by SynthesisHub Advance Scientific Research in Systematic Reviews in Pharmacy
- Vol. 9 (1) , 83-84
Quality Assessment of Systematic Reviews of Health Economic Evaluations: Pitfalls with the Application of the PRISMA Statement. Comment on Quang et al. (Sys Rev Pharm. 2017;8(1):52-61)
- 31 July 2018
- Published by SynthesisHub Advance Scientific Research in Systematic Reviews in Pharmacy
- Vol. 9 (1) , 83-84
Open AccessQuality Assessment of Systematic Reviews of Health Economic Evaluations: Pitfalls with the Application of the PRISMA Statement. Comment on Quang et al. (Sys Rev Pharm. 2017;8(1):52-61)
- 18 July 2018
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 18 (5) , 475-486
The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?
Introduction: The efficiency-frontier approach (EFA) to health economic evaluation aims to benchmark the relative efficiency of new drugs with the incremental cost-effectiveness ratios (ICERs) of non-dominated comparators. By explicitly considering any differences in health outcomes and costs, it enhances the internal reference pricing (IRP) policy that was officially endorsed by Germany as the first country worldwide in 1989. However, the EFA has been repeatedly criticized since its official endorsement in 2009. Areas covered: This perspective aims to stimulate the debate by discussing whether the main objections to the EFA are technically valid, irrespective of national contextual factors in Germany with reservations towards using cost-per-quality-adjusted life year (QALY) thresholds. Moreover, we comparatively assessed whether the objections are truly unique to the EFA or apply equally to IRP and cost-effectiveness thresholds. Expert commentary: The plethora of objections to the EFA (n = 20) has obscured that many objections are neither technically valid nor unique to the EFA. Compared with cost-effectiveness thresholds, only two objections apply uniquely to the EFA and concern intended key properties: (1) no external thresholds are needed and (2) the EFA is sensitive to price changes of comparators. Combining these policies and developing them further are under-utilized research areas.
- 18 July 2018
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 18 (5) , 475-486
The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?
Introduction: The efficiency-frontier approach (EFA) to health economic evaluation aims to benchmark the relative efficiency of new drugs with the incremental cost-effectiveness ratios (ICERs) of non-dominated comparators. By explicitly considering any differences in health outcomes and costs, it enhances the internal reference pricing (IRP) policy that was officially endorsed by Germany as the first country worldwide in 1989. However, the EFA has been repeatedly criticized since its official endorsement in 2009. Areas covered: This perspective aims to stimulate the debate by discussing whether the main objections to the EFA are technically valid, irrespective of national contextual factors in Germany with reservations towards using cost-per-quality-adjusted life year (QALY) thresholds. Moreover, we comparatively assessed whether the objections are truly unique to the EFA or apply equally to IRP and cost-effectiveness thresholds. Expert commentary: The plethora of objections to the EFA (n = 20) has obscured that many objections are neither technically valid nor unique to the EFA. Compared with cost-effectiveness thresholds, only two objections apply uniquely to the EFA and concern intended key properties: (1) no external thresholds are needed and (2) the EFA is sensitive to price changes of comparators. Combining these policies and developing them further are under-utilized research areas.
- Open Access
- 10 January 2018
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 3 (1)
Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants
Background: Estimating input costs for Markov models in health economic evaluations requires health state–specific costing. This is a challenge in mental illnesses such as depression, as interventions are not clearly related to health states. We present a hybrid approach to health state–specific cost estimation for a German health economic evaluation of antidepressants. Methods: Costs were determined from the perspective of the community of persons insured by statutory health insurance (“SHI insuree perspective”) and included costs for outpatient care, inpatient care, drugs, and psychotherapy. In an additional step, costs for rehabilitation and productivity losses were calculated from the societal perspective. We collected resource use data in a stepwise hierarchical approach using SHI claims data, where available, followed by data from clinical guidelines and expert surveys. Bottom-up and top-down costing approaches were combined. Results: Depending on the drug strategy and health state, the average input costs varied per patient per 8-week Markov cycle. The highest costs occurred for agomelatine in the health state first-line treatment (FT) (“FT relapse”) with €506 from the SHI insuree perspective and €724 from the societal perspective. From both perspectives, the lowest costs (excluding placebo) were €55 for selective serotonin reuptake inhibitors in the health state “FT remission.” Conclusion: To estimate costs in health economic evaluations of treatments for depression, it can be necessary to link different data sources and costing approaches systematically to meet the requirements of the decision-analytic model. As this can increase complexity, the corresponding calculations should be presented transparently. The approach presented could provide useful input for future models.
- 10 January 2018
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 3 (1)
Open AccessEstimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants
Background: Estimating input costs for Markov models in health economic evaluations requires health state–specific costing. This is a challenge in mental illnesses such as depression, as interventions are not clearly related to health states. We present a hybrid approach to health state–specific cost estimation for a German health economic evaluation of antidepressants. Methods: Costs were determined from the perspective of the community of persons insured by statutory health insurance (“SHI insuree perspective”) and included costs for outpatient care, inpatient care, drugs, and psychotherapy. In an additional step, costs for rehabilitation and productivity losses were calculated from the societal perspective. We collected resource use data in a stepwise hierarchical approach using SHI claims data, where available, followed by data from clinical guidelines and expert surveys. Bottom-up and top-down costing approaches were combined. Results: Depending on the drug strategy and health state, the average input costs varied per patient per 8-week Markov cycle. The highest costs occurred for agomelatine in the health state first-line treatment (FT) (“FT relapse”) with €506 from the SHI insuree perspective and €724 from the societal perspective. From both perspectives, the lowest costs (excluding placebo) were €55 for selective serotonin reuptake inhibitors in the health state “FT remission.” Conclusion: To estimate costs in health economic evaluations of treatments for depression, it can be necessary to link different data sources and costing approaches systematically to meet the requirements of the decision-analytic model. As this can increase complexity, the corresponding calculations should be presented transparently. The approach presented could provide useful input for future models.
- 1 October 2017
- Published by Duncker & Humblot GmbH in Sozialer Fortschritt
- Vol. 66 (10) , 651-673
Effizienzbewertung im Rahmen des GKV-Versorgungsstärkungsgesetzes: Was kann die Gesundheitsökonomie hierzu beitragen?
Mit dem GKV-Versorgungsstärkungsgesetz erhielt der Gemeinsame Bundesausschuss den Auftrag, neue Versorgungsformen und -forschungsprojekte zu fördern. Als Förderkriterien werden u.a. die Versorgungseffizienz und die Verhältnismäßigkeit von Implementierungskosten und dem damit verbundenen Nutzen genannt. Für die Versorgungsforschung bedeutet dies, dass auch gesundheitsökonomische Studien nun an Relevanz gewinnen. Dabei wirken der sozialrechtlich verankerte ordnungspolitische Rahmen über das Wirtschaftlichkeitsgebot und die Beitragssatzstabilität als Determinanten der Effizienzbewertung. Allerdings ist die Evaluation komplexer Interventionen wie neue Versorgungsformen auch mit entsprechenden methodischen Herausforderungen verknüpft. Die aktuellen nationalen und internationalen Studienbeispiele zu komplexen Interventionen verdeutlichen das Potenzial und den Beitrag der gesundheitsökonomischen Disziplin zur Effizienzsteigerung in der Versorgung. Evaluating Efficiency within the Act to improve the he...
- 1 October 2017
- Published by Duncker & Humblot GmbH in Sozialer Fortschritt
- Vol. 66 (10) , 651-673
Effizienzbewertung im Rahmen des GKV-Versorgungsstärkungsgesetzes: Was kann die Gesundheitsökonomie hierzu beitragen?
Mit dem GKV-Versorgungsstärkungsgesetz erhielt der Gemeinsame Bundesausschuss den Auftrag, neue Versorgungsformen und -forschungsprojekte zu fördern. Als Förderkriterien werden u.a. die Versorgungseffizienz und die Verhältnismäßigkeit von Implementierungskosten und dem damit verbundenen Nutzen genannt. Für die Versorgungsforschung bedeutet dies, dass auch gesundheitsökonomische Studien nun an Relevanz gewinnen. Dabei wirken der sozialrechtlich verankerte ordnungspolitische Rahmen über das Wirtschaftlichkeitsgebot und die Beitragssatzstabilität als Determinanten der Effizienzbewertung. Allerdings ist die Evaluation komplexer Interventionen wie neue Versorgungsformen auch mit entsprechenden methodischen Herausforderungen verknüpft. Die aktuellen nationalen und internationalen Studienbeispiele zu komplexen Interventionen verdeutlichen das Potenzial und den Beitrag der gesundheitsökonomischen Disziplin zur Effizienzsteigerung in der Versorgung. Evaluating Efficiency within the Act to improve the he...
- 3 August 2017
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 24 (10) , 1375-1382
Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO)
Evidence-based complementary treatment options for multiple sclerosis (MS) are limited. To investigate the effect of hippotherapy plus standard care versus standard care alone in MS patients. A total of 70 adults with MS were recruited in five German centers and randomly allocated to the intervention group (12 weeks of hippotherapy) or the control group. Primary outcome was the change in the Berg Balance Scale (BBS) after 12 weeks, and further outcome measures included fatigue, pain, quality of life, and spasticity. Covariance analysis of the primary endpoint resulted in a mean difference in BBS change of 2.33 (95% confidence interval (CI): 0.03–4.63, p = 0.047) between intervention (n = 32) and control (n = 38) groups. Benefit on BBS was largest for the subgroup with an Expanded Disability Status Scale (EDSS) ⩾ 5 (5.1, p = 0.001). Fatigue (−6.8, p = 0.02) and spasticity (−0.9, p = 0.03) improved in the intervention group. The mean difference in change between groups was 12.0 (p < 0.001) in physical health score and 14.4 (p < 0.001) in mental health score of Multiple Sclerosis Quality of Life-54 (MSQoL-54). Hippotherapy plus standard care, while below the threshold of a minimal clinically important difference, significantly improved balance and also fatigue, spasticity, and quality of life in MS patients.
- 3 August 2017
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 24 (10) , 1375-1382
Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO)
Evidence-based complementary treatment options for multiple sclerosis (MS) are limited. To investigate the effect of hippotherapy plus standard care versus standard care alone in MS patients. A total of 70 adults with MS were recruited in five German centers and randomly allocated to the intervention group (12 weeks of hippotherapy) or the control group. Primary outcome was the change in the Berg Balance Scale (BBS) after 12 weeks, and further outcome measures included fatigue, pain, quality of life, and spasticity. Covariance analysis of the primary endpoint resulted in a mean difference in BBS change of 2.33 (95% confidence interval (CI): 0.03–4.63, p = 0.047) between intervention (n = 32) and control (n = 38) groups. Benefit on BBS was largest for the subgroup with an Expanded Disability Status Scale (EDSS) ⩾ 5 (5.1, p = 0.001). Fatigue (−6.8, p = 0.02) and spasticity (−0.9, p = 0.03) improved in the intervention group. The mean difference in change between groups was 12.0 (p < 0.001) in physical health score and 14.4 (p < 0.001) in mental health score of Multiple Sclerosis Quality of Life-54 (MSQoL-54). Hippotherapy plus standard care, while below the threshold of a minimal clinically important difference, significantly improved balance and also fatigue, spasticity, and quality of life in MS patients.
- 18 May 2017
- Published by Georg Thieme Verlag KG in Das Gesundheitswesen
- Vol. 80 (08/09) , 744-753
Checkliste zur Erstellung und Bewertung von Krankheitskostenstudien
Hintergrund Krankheitskostenstudien sind wichtige Instrumente, um die sozioökonomische Krankheitslast für definierte Erkrankungen abzuschätzen. Sie liefern der Versorgungsforschung sowie der Gesundheitspolitik wichtige Informationen zur Kostenstruktur einer Erkrankung, dem sich daraus ableitenden Forschungsbedarf, Ansätze zur Versorgungsoptimierung sowie zu den monetären Auswirkungen aus unterschiedlichen Perspektiven. Aufgrund der Heterogenität verfügbarer Krankheitskostenstudien entwickelte die Arbeitsgemeinschaft (AG) Gesundheitsökonomie des Deutschen Netzwerks Versorgungsforschung (DNVF) e.V. in Abstimmung mit der Deutschen Gesellschaft für Gesundheitsökonomie (DGGÖ) e.V. für Deutschland ein Instrument zur Planung/Durchführung und Beurteilung von Krankheitskostenstudien. Methodik Aufbau und Inhalt der generischen Checkliste wurden von der AG konzipiert, konsentiert und nachfolgend in einem Pretest überprüft. Die Checkliste basiert auf einer systematischen Literaturrecherche zu nationalen und bereits vorliegenden internationalen Checklisten sowie Leitlinien und Empfehlungen für die Erstellung und Bewertung von Krankheitskostenstudien und gesundheitsökonomischen Evaluationen. Ergebnis Aus der Literaturrecherche (N=2 454) konnten 58 Referenzen zur Identifizierung und Begründung von Kriterien für die Erstellung der Checkliste genutzt werden. Nach Durchführung und Auswertung des Pretests wurden 6 Dimensionen in die Checkliste einbezogen: (i) Allgemeine Aspekte, (ii) Identifikation der Ressourcen, (iii) Beschreibung und Quantifizierung der Ressourcenverbräuche, (iv) Bewertung der Ressourcen (v) Auswertung und Ergebnisdarstellung sowie (vi) Diskussion und Schlussfolgerung. Insgesamt werden die einzelnen Dimensionen über 37 Kriterien operationalisiert. Schlussfolgerung Die Checkliste ist ein erster Ansatz, die transparente Darstellung und das Verständnis von Krankheitskostenstudien im Hinblick auf Ausmaß, Zusammensetzung und Entwicklung der sozioökonomischen Krankheitslast ausgewählter Erkrankungen zu verbessern. Sie unterstützt die Vergleichbarkeit verschiedener Analysen und erleichtert die Studienkonzeption. Background Cost-of-illness (CoI) studies are important instruments for estimating the socioeconomic burden of specified diseases. CoI studies provide important information about the cost structure of a disease, the resulting research need, approaches to improve aspects of care and, monetary consequences from different perspectives. This information can be useful for healthcare research and health policy. Due to heterogeneity of available Cost-of-Illness studies, the working group ‘Health Economics’ of the German Network for Healthcare Research (DNVF) in accordance with the German Society for Health Economics (DGGÖ) developed an instrument for the planning, conduct and assessment of CoI studies. Methods The checklist was developed based on a systematic literature search of published national and international checklists as well as guidelines and recommendations for development and assessment of CoI studies and health economic evaluations. Structure and subject matter of the generic checklist was designed, approved and, finally, examined in a pretest by the working group. Results Based on the results of the literature search (n=2 454), 58 articles were used for the identification of relevant criteria for the checklist. With respect to the results of the pretest, 6 dimensions were included in the checklist: (i) general aspects, (ii) identification of resources, (iii) description and quantification of resource consumption, (iv) valuation of resources (v) analysis and presentation of results and (vi) discussion and conclusion. In total, the 6 dimensions were operationalized through 37 items. Conclusion This checklist is an initial approach to improve transparency and understanding of CoI studies in terms of the extent, structure and development of the socioeconomic burden of diseases. The checklist supports the comparability of different studies and facilitates study conception. * geteilte Erstautorenschaft
- 18 May 2017
- Published by Georg Thieme Verlag KG in Das Gesundheitswesen
- Vol. 80 (08/09) , 744-753
Checkliste zur Erstellung und Bewertung von Krankheitskostenstudien
Hintergrund Krankheitskostenstudien sind wichtige Instrumente, um die sozioökonomische Krankheitslast für definierte Erkrankungen abzuschätzen. Sie liefern der Versorgungsforschung sowie der Gesundheitspolitik wichtige Informationen zur Kostenstruktur einer Erkrankung, dem sich daraus ableitenden Forschungsbedarf, Ansätze zur Versorgungsoptimierung sowie zu den monetären Auswirkungen aus unterschiedlichen Perspektiven. Aufgrund der Heterogenität verfügbarer Krankheitskostenstudien entwickelte die Arbeitsgemeinschaft (AG) Gesundheitsökonomie des Deutschen Netzwerks Versorgungsforschung (DNVF) e.V. in Abstimmung mit der Deutschen Gesellschaft für Gesundheitsökonomie (DGGÖ) e.V. für Deutschland ein Instrument zur Planung/Durchführung und Beurteilung von Krankheitskostenstudien. Methodik Aufbau und Inhalt der generischen Checkliste wurden von der AG konzipiert, konsentiert und nachfolgend in einem Pretest überprüft. Die Checkliste basiert auf einer systematischen Literaturrecherche zu nationalen und bereits vorliegenden internationalen Checklisten sowie Leitlinien und Empfehlungen für die Erstellung und Bewertung von Krankheitskostenstudien und gesundheitsökonomischen Evaluationen. Ergebnis Aus der Literaturrecherche (N=2 454) konnten 58 Referenzen zur Identifizierung und Begründung von Kriterien für die Erstellung der Checkliste genutzt werden. Nach Durchführung und Auswertung des Pretests wurden 6 Dimensionen in die Checkliste einbezogen: (i) Allgemeine Aspekte, (ii) Identifikation der Ressourcen, (iii) Beschreibung und Quantifizierung der Ressourcenverbräuche, (iv) Bewertung der Ressourcen (v) Auswertung und Ergebnisdarstellung sowie (vi) Diskussion und Schlussfolgerung. Insgesamt werden die einzelnen Dimensionen über 37 Kriterien operationalisiert. Schlussfolgerung Die Checkliste ist ein erster Ansatz, die transparente Darstellung und das Verständnis von Krankheitskostenstudien im Hinblick auf Ausmaß, Zusammensetzung und Entwicklung der sozioökonomischen Krankheitslast ausgewählter Erkrankungen zu verbessern. Sie unterstützt die Vergleichbarkeit verschiedener Analysen und erleichtert die Studienkonzeption. Background Cost-of-illness (CoI) studies are important instruments for estimating the socioeconomic burden of specified diseases. CoI studies provide important information about the cost structure of a disease, the resulting research need, approaches to improve aspects of care and, monetary consequences from different perspectives. This information can be useful for healthcare research and health policy. Due to heterogeneity of available Cost-of-Illness studies, the working group ‘Health Economics’ of the German Network for Healthcare Research (DNVF) in accordance with the German Society for Health Economics (DGGÖ) developed an instrument for the planning, conduct and assessment of CoI studies. Methods The checklist was developed based on a systematic literature search of published national and international checklists as well as guidelines and recommendations for development and assessment of CoI studies and health economic evaluations. Structure and subject matter of the generic checklist was designed, approved and, finally, examined in a pretest by the working group. Results Based on the results of the literature search (n=2 454), 58 articles were used for the identification of relevant criteria for the checklist. With respect to the results of the pretest, 6 dimensions were included in the checklist: (i) general aspects, (ii) identification of resources, (iii) description and quantification of resource consumption, (iv) valuation of resources (v) analysis and presentation of results and (vi) discussion and conclusion. In total, the 6 dimensions were operationalized through 37 items. Conclusion This checklist is an initial approach to improve transparency and understanding of CoI studies in terms of the extent, structure and development of the socioeconomic burden of diseases. The checklist supports the comparability of different studies and facilitates study conception. * geteilte Erstautorenschaft
- 1 May 2017
- Published by Elsevier in The Journal of Pediatrics
- Vol. 184, 244-245.e1
Conceptual Design of Future Children's Hospitals in Europe: The Role of Caregivers in Transferring New Concepts from Theory into Practice
- 1 May 2017
- Published by Elsevier in The Journal of Pediatrics
- Vol. 184, 244-245.e1
Conceptual Design of Future Children's Hospitals in Europe: The Role of Caregivers in Transferring New Concepts from Theory into Practice